ArticleFrontiers in immunology2023

A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy.

Dan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.